CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd. (CLGN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
clgn · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$14.00
Consensus
$12.50
+3278.4% upside
Low
$11.00
Median: $12.5 · Last Close: $0.37
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.36 | ↓ 3.04% |
1-day model range: $0.35–$0.36. Peak: $0.36 (-3.04%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CLGN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-02-06 | D. Boral Capital | Downgrade ↓ | Buy→Hold |
| 2025-11-28 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-10-20 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-09-16 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-08-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-20 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-05-30 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-05-28 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-03-27 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-02-12 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on CollPlant Biotechnologies Ltd. (CLGN) stock. Of the recent 27 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover CLGN.
Analyst Recommendation Trends
CLGN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 33.3% YoY
Revenue Next Year
$3M
↑ 25.0% YoY
EPS This Year
$-0.59
EPS Next Year
$-0.18
↓ 69.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CLGN EPS of $-0.59 for the current fiscal year, based on estimates from 1 analysts. The CLGN revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CLGN stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CLGN price target is $12.50 (+3278.4% upside), with an analyst consensus of Buy.
The CLGN short-term stock prediction for tomorrow is $0.36 (-3.04%).
CollPlant Biotechnologies Ltd. trades on NASDAQ under the ticker CLGN. The CLGN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
CLGN forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month CLGN price target is $12.50, with a high forecast of $14.00 and a low of $11.00. The median price target is shown in the chart above when available. This implies +3278.4% potential upside from the current price of $0.37.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.